Versant and Eli Lilly back $100 million gene therapy startup
1 outlet · 0L · 1C · 0R
First reported
1 / 1
We're still gathering coverage of this story.
A neutral account and the side-by-side comparison are written once at least 2 outlets have reported it. Here is the coverage so far.
Left0 articles
No coverage yet.
Centre1 article
Right0 articles
No coverage yet.
- 16 Nov 10:00 First STATN STAT+: Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues
Times are when each article was published, or when we first saw it if the outlet gave no time.
Ask about this story
Loading…
